ProSomnus RPMO2 OSA Device (RPMO2 OSA)
Prosomnus Sleep Technologies · Decision date Apr 6, 2026
What did the FDA decide?
FDA records K252765 as a 510(k) premarket notification, with a decision dated Apr 6, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Dental
- Decision date
- Apr 6, 2026
Regulatory record facts
- Identifier
- K252765
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Prosomnus Sleep Technologies
- Product code
- PLC
- Decision code
- SESE
- Decision date
- Apr 6, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Sleep Appliances With Patient Monitoring.
- Applicant
- Prosomnus Sleep Technologies
- Product code
- PLC
- FDA device class
- 2
FDA decision timeline
K252765 received
Application receipt date recorded by FDA.
K252765 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code PLC
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
iNOS intraoral biosensorK254304 | Achaemenid, LLC | 510(k) clearance | Aug 25, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Prosomnus Sleep Technologies
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Pleasanton, CA
Sources and methodology
- Original FDA record: K252765
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records